EU prepares to control 5-IT
A proposal has been sent to the Council of the European Union to subject substance 5-(2-aminopropyl)indole to control measures
10th September 2013
The European Commission has put forth a proposal to the Council which would ensure EU wide control of 5-IT (5-(2-aminopropyl)indole.
The proposal concluded that here have been a total of 24 fatalities registered in four Member States between April and August 2012, where 5-(2-aminopropyl)indole alone, or in combination with other substances, has been detected in post-mortem samples. While it was not possible to determine with certainty the role of 5-(2-aminopropyl)indole in all of the fatalities, in some cases it has been specifically noted in the cause of death. If this new psychoactive substance were to become more widely available and used, the implications for individual and public health could be significant.
The existing information and data suggests that the acute toxicity of 5-(2-aminopropyl)indole can provoke adverse effects in humans, such as tachycardia and hyperthermia, and may also cause mydriasis, agitation and tremor. 5-(2-aminopropyl)indole may interact with other substances, including medical products and stimulants that act on the monoaminergic system.
5-(2-aminopropyl)indole has no known, established or acknowledged medical value or use, and there is no marketing authorisation covering this new psychoactive substance in the Union. Apart from its use as an analytical reference standard and in scientific research, there is no indication that it is being used for other purposes. (8) 5-(2-aminopropyl)indole has not been under assessment and is currently not under assessment by the United Nations system. Two Member States control this new psychoactive substance under national legislation complying with the obligations of the 1971 United Nations Convention on Psychotropic Substances. Five European countries apply legislation on new psychoactive substances, dangerous goods or medicines to control 5-(2-aminopropyl)indole.